PMID: 6985833Jan 15, 1980Paper

Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma

Cancer
M S PiverL E Blumenson

Abstract

A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. One hundred fourteen patients were included in the study: 70 received Delalutin and 44 Depo-Provera. There was no significant increase in the objective response or survival between the Delalutin or Depo-Provera patients. Of the 114 patients, 15.8% achieved an objective response, with 7.0% being complete responders. There was no significant increase in objective response to Delalutin or Depo-Provera in relationship to the size of the tumor masses, the number of metastases, site of metastases, histologic grade of the primary, histologic grade of recurrence or metastases, or prior radiation therapy. The only significant correlate was that patients whose disease recurred 3 or more years after the initial therapy had a significant (P = 0.01) increase in response (33.3%) compared to those with recurrence less than 3 years after their original treatment (8.3%).

References

Feb 1, 1978·The Surgical Clinics of North America·J P Smith
Jun 1, 1977·American Journal of Obstetrics and Gynecology·F M MuggiaS L Romney

❮ Previous
Next ❯

Citations

Jan 31, 2004·Gynecologic Oncology·Charles W WhitneyUNKNOWN Gynecologic Oncology Group study
Nov 1, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S LoiblM Kaufmann
Apr 20, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S B Decruze, J A Green
Jul 28, 2010·The Oncologist·J Alejandro Rauh-Hain, Marcela G Del Carmen
Feb 24, 2000·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·A Gadducci, A R Genazzani
Jun 30, 2009·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Angiolo GadducciAndrea Riccardo Genazzani
Sep 11, 2010·Expert Opinion on Emerging Drugs·Ozden AltundagAli Ayhan
Apr 25, 2006·Gynecologic Oncology·Robert E BristowDeborah K Armstrong
Nov 28, 2000·Expert Opinion on Investigational Drugs·L Elit, H Hirte
Mar 18, 1999·Hematology/oncology Clinics of North America·M A Quinn
Jan 2, 2007·Cancer Treatment Reviews·D PectasidesT Economopoulos
Oct 15, 1987·Cancer·T ThigpenR McGehee
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Fani KokkaAndrew Bryant
Jul 24, 2004·Expert Review of Anticancer Therapy·Alessandro D SantinJuan J Roman
May 2, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F H van WijkHelena C van Doorn
May 2, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F H van WijkH C van Doorn
Apr 4, 2014·Journal of the Chinese Medical Association : JCMA·Wen-Ling LeePeng-Hui Wang
Dec 17, 2008·Cancer Control : Journal of the Moffitt Cancer Center·Sarah M Temkin, Gini Fleming
Mar 5, 2013·American Journal of Obstetrics and Gynecology·Steve N CaritisRaman Venkataramanan
Jul 31, 2001·Best Practice & Research. Clinical Obstetrics & Gynaecology·E Podczaski, R Mortel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.